CAC
SRPT icon

Cowen and Company’s Sarepta Therapeutics SRPT Stock Holding History

Cowen and Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,012
Closed -$1.64M – 714
2023
Q4 		$1.64M Buy
+17,012
New +$1.63M 0.11% 123
2022
Q2 		– Sell
-7,218
Closed -$564K – 741
2022
Q1 		$564K Buy
7,218
+6,356
+737% +$487K 0.05% 144
2021
Q4 		$78K Sell
862
-11,039
-93% -$944K 0.01% 392
2021
Q3 		$1.1M Buy
+11,901
New +$917K 0.05% 134
2020
Q2 		– Sell
-3,589
Closed -$351K – 473
2020
Q1 		$351K Buy
3,589
+444
+14% +$50.8K 0.08% 146
2019
Q4 		$406K Buy
+3,145
New +$317K 0.04% 140

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cowen and Company's SRPT Position: Q1 2024 in Review

Cowen and Company sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 17,012 shares — an estimated $1.64M sold.

Cowen and Company first reported a position in SRPT in Q4 2019 and held it in 6 quarters. The position peaked at $1.64M in Q4 2023. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Cowen and Company reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 17,012 Sarepta Therapeutics shares in Q1 2024, an estimated $1.64M.
  • Cowen and Company first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 6 quarters.
  • Cowen and Company's Sarepta Therapeutics position peaked at $1.64M in Q4 2023.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.